Article- With flibanserin approval, a complicated drug takes the spotlight
Ever since Viagra was first approved for men, female advocates have been waiting for their “little pink pill.” On August 18, the day arrived: Flibanserin — a failed antidepressant — received approval from the Food and Drug Administration to boost sexual desire in women. Immediately articles and blog posts were published that questioned the new drug. Some noted its low efficacy and interactions with alcohol and with other medications, and cast a leery eye at the strong advocacy associated with the drug’s approval. Supporters and some patients praised the decision, saying it opened the door for other companies to develop alternatives.
Flibanserin, soon to be marketed as Addyi, has been in clinical trials to treat low desire since the mid-2000s. It has been previously rejected by the FDA, once in 2010 over concerns of its efficacy and once again in 2013, when the FDA questioned whether the side effect risks outweighed the benefits. Sprout Pharmaceuticals appealed the decision and after additional safety studies, the drug finally got approval. - Read More (Source - Science News, Images- Sprout Pharmaceuticals)
The New Science of How to Quit Smoking, as shown in a recent Neuropsychopharmacology research article.
Mechanism of action of two new synthetic drugs unravelled for the first time, as shown in recent Neuropsychopharmacology research article.
Omega-3 fatty acids help improve boys' attention spans, as shown in recent Neuropsychopharmacology research article.